International Journal of Molecular Sciences (May 2024)

A Humanized and Viable Animal Model for Congenital Adrenal Hyperplasia–<i>CYP21A2</i>-R484Q Mutant Mouse

  • Shamini Ramkumar Thirumalasetty,
  • Tina Schubert,
  • Ronald Naumann,
  • Ilka Reichardt,
  • Marie-Luise Rohm,
  • Dana Landgraf,
  • Florian Gembardt,
  • Mirko Peitzsch,
  • Michaela F. Hartmann,
  • Mihail Sarov,
  • Stefan A. Wudy,
  • Nicole Reisch,
  • Angela Huebner,
  • Katrin Koehler

DOI
https://doi.org/10.3390/ijms25105062
Journal volume & issue
Vol. 25, no. 10
p. 5062

Abstract

Read online

Congenital Adrenal Hyperplasia (CAH) is an autosomal recessive disorder impairing cortisol synthesis due to reduced enzymatic activity. This leads to persistent adrenocortical overstimulation and the accumulation of precursors before the blocked enzymatic step. The predominant form of CAH arises from mutations in CYP21A2, causing 21-hydroxylase deficiency (21-OHD). Despite emerging treatment options for CAH, it is not always possible to physiologically replace cortisol levels and counteract hyperandrogenism. Moreover, there is a notable absence of an effective in vivo model for pre-clinical testing. In this work, we developed an animal model for CAH with the clinically relevant point mutation p.R484Q in the previously humanized CYP21A2 mouse strain. Mutant mice showed hyperplastic adrenals and exhibited reduced levels of corticosterone and 11-deoxycorticosterone and an increase in progesterone. Female mutants presented with higher aldosterone concentrations, but blood pressure remained similar between wildtype and mutant mice in both sexes. Male mutant mice have normal fertility with a typical testicular appearance, whereas female mutants are infertile, exhibit an abnormal ovarian structure, and remain in a consistent diestrus phase. Conclusively, we show that the animal model has the potential to contribute to testing new treatment options and to prevent comorbidities that result from hormone-related derangements and treatment-related side effects in CAH patients.

Keywords